Kite gives it­self a lit­tle more time to fin­ish FDA ap­pli­ca­tion for KTE-C19

Kite Phar­ma has giv­en it­self un­til Q1 2017 to com­plete the BLA fil­ing for KTE-C19, its pi­o­neer­ing en­gi­neered T-cell ther­a­py. That’s a slight push­back of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.